BD (Becton, Dickinson and Company) announced on April 23, 2025, that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and commercially launched the Phasix™ ST Umbilical Hernia Patch. This product is the first and only fully absorbable hernia patch on the market designed specifically for umbilical hernias.
The Phasix™ ST Umbilical Hernia Patch is composed of Poly-4-hydroxybutyrate (P4HB), a biologically-derived material, and includes a hydrogel barrier based on Sepra® Technology. It can be deployed using the same surgical technique as traditional permanent mesh procedures, offering surgeons material optionality.
Recent survey data indicates that 60% of patients prefer a non-permanent mesh option for hernia repair, and over 70% of surgeons are willing to respond to patient mesh preferences. This launch expands BD's Phasix™ Mesh absorbable product family, which has over 385,000 implants globally and proven clinical outcomes.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.